Wednesday, June 25

Chennai: The Central Council for Research in Homoeopathy (CCRH), an autonomous body under the Ministry of Ayush, Government of India, has officially signed a Memorandum of Understanding (MoU) with SRM Institute of Science and Technology (SRMIST). This partnership aims to enhance collaborative research efforts utilising the advanced infrastructure of SRMIST. The signing ceremony was attended by key figures from both organisations, including SRMIST Registrar Prof. S. Ponnusamy, Dean of Research Prof. Neppolian, and IIISM Coordinator Dr. R.C. Satish Kumar. From CCRH, the delegation included Director General Dr. Subash Kaushik and other prominent members such as Dr. Digvijay Verma, Dr. Pankaj Gupta, Dr. Karthikeyan, and Dr. Kolli Raju from the Clinical Research Unit (Homoeopathy) in Chennai.

The MoU establishes a framework for cooperation between CCRH and the Interdisciplinary Institute of Indian System of Medicine (IIISM) at SRMIST’s Directorate of Research. It seeks to create mutually beneficial opportunities for joint Ph.D. research programs, as well as graduate and postgraduate dissertation initiatives across various fields, including Homoeopathy, Pharmacology, Botany, Chemistry, Pharmacognosy, Molecular Biology, and Biotechnology. This collaboration marks a significant step toward advancing research in interdisciplinary sciences and promoting the integration of traditional and modern medical practices.

Share.
Leave A Reply

Doctors Post is a news portal tailored to provide current news & updates on issues related exclusively to medical & healthcare professionals. The content of Doctor Post is judiciously authored by a dedicated team of legal experts, doctors and reporters.  The intent of the content is to expeditiously update doctor’s information & news necessary for the smooth functioning of their profession.

© 2024 Doctor Post. All Rights Reserved. Created and Maintained by Creative web Solution

Disclaimer: Use of the site is governed by our terms of use, privacy policy, and advertisement policy. For further details, please refer to our Disclaimer.

Exit mobile version